These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9529516)

  • 21. Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type.
    Am J Health Syst Pharm; 1998 Jan; 55(2):104. PubMed ID: 9465969
    [No Abstract]   [Full Text] [Related]  

  • 22. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622
    [No Abstract]   [Full Text] [Related]  

  • 23. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
    Lips P; Netelenbos JC
    Ned Tijdschr Geneeskd; 1996 Jun; 140(23):1215-7. PubMed ID: 8700270
    [No Abstract]   [Full Text] [Related]  

  • 26. Medications for postmenopausal osteoporosis prevention.
    Harv Womens Health Watch; 2002 Dec; 10(4):6-7. PubMed ID: 12499127
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of novel antiresorptive agents for the prevention and treatment of osteoporosis.
    Meier CA
    Eur J Endocrinol; 1998 Jul; 139(1):18-9. PubMed ID: 9703373
    [No Abstract]   [Full Text] [Related]  

  • 28. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 30. [Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
    Oliaro A
    Minerva Ginecol; 1998 Mar; 50(3):XII-XIII. PubMed ID: 9595915
    [No Abstract]   [Full Text] [Related]  

  • 31. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
    Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Selective estrogen receptor modulators].
    Bornkessel B
    Med Monatsschr Pharm; 1998 Jul; 21(7):194-6. PubMed ID: 9691626
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
    MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
    [No Abstract]   [Full Text] [Related]  

  • 40. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.